PI3K signaling pathway in normal B cells and indolent B-cell malignancies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PI3K signaling pathway in normal B cells and indolent B-cell malignancies

Published:2016-12 Issue:6 Volume:43 Page:647-654
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Pongas Georgios,Cheson Bruce D.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference83 articles.

1. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

2. Gilead stops six trials adding idelalisib to other drugs. www.medscape.com. Accessed March 14, 2016

3. Introduction;Yuan;Phosphoinositide 3-kinase in health and disease,2010

4. Signaling by the phosphoinositide 3-kinase family in immune cells;Okkenhaug;Ann Rev Immunol,2013

5. Introduction. Phosphoinositide 3-kinase in health and disease;Yuan,2010

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

2. Obesity and Risk for Lymphoma: Possible Role of Leptin;International Journal of Molecular Sciences;2022-12-08

3. The role of Syk phosphorylation in Fc receptor mediated mIgM+ B lymphocyte phagocytosis in flounder (Paralichthys olivaceus);Fish & Shellfish Immunology;2022-11

4. Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study;International Journal of Hematology;2022-09-15

5. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial;The Lancet Oncology;2022-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3